Ocular haemorrhages under antithrombotic therapy: risk factors, management and clinical perspectives
Klinische Monatsblätter für Augenheilkunde · 30.09.2026
DOI: 10.1055/a-2937-0560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 30.09.2026. Verfasst von Christoph Sucker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Coagumed Gerinnungszentrum, Berlin, Deutschland, Germany, Berlin. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Spontaneous ocular haemorrhages under antithrombotic therapy are rare but can lead to persistent visual impairment up to blindness. Despite increasing prescriptions of antithrombotic medications, systematic overviews on incidence, risk factors, and management are lacking. Patients and Methods Based on a selective literature review, current clinical studies, registry data, and epidemiologic analyses on spontaneous ocular haemorrhages under oral/parenteral anticoagulation and antiplatelet therapy were evaluated. The evidence was summarized regarding incidence, risk constellations, acute bleeding management, and therapy resumption.
Results
The risk of ocular haemorrhages varies significantly depending on medication, comorbidity, and combination therapy. Elderly patients with arterial hypertension, impaired renal function, and pre-existing eye diseases are particularly at risk. Dual antiplatelet therapy and combinations of anticoagulants and antiplatelet agents significantly increase the risk. Among oral anticoagulants, apixaban shows the most favourable ocular bleeding profile. Acute management strategies range from systemic reversal (e.g., idarucizumab, andexanet alfa) to ophthalmologic interventions (laser, vitrectomy). Therapy resumption should be coordinated interdisciplinarily.
Conclusions
Ocular haemorrhages under antithrombotic therapy require prompt, risk-adapted management. The choice of anticoagulant, control of modifiable risk factors, and clear decision algorithms for resumption of antithrombotic therapy are essential to prevent both vision loss and thromboembolic complications.
Autor:innen und Institutionen
- Coagumed Gerinnungszentrum, Berlin, Deutschland, Germany, Berlin.
- Augentagesklinik Zehlendorf, Germany, Berlin.
- Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Augenklinik, Germany, Berlin.
- Universitätsspital Basel Augenklinik, Augenklinik, BS, Switzerland, Basel.
ORCID-Profile: Nicolas Feltgen
Zitieren
APA
Sucker, C., Zeitz, O., & Feltgen, N. (2026). Ocular haemorrhages under antithrombotic therapy: risk factors, management and clinical perspectives. Klinische Monatsblätter für Augenheilkunde. https://doi.org/10.1055/a-2937-0560
Vancouver
Sucker C, Zeitz O, Feltgen N. Ocular haemorrhages under antithrombotic therapy: risk factors, management and clinical perspectives. Klinische Monatsblätter für Augenheilkunde. 2026. doi:10.1055/a-2937-0560
BibTeX
@article{Sucker2026,
author = {Sucker, Christoph and Zeitz, Oliver and Feltgen, Nicolas},
title = {Ocular haemorrhages under antithrombotic therapy: risk factors, management and clinical perspectives},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2026},
doi = {10.1055/a-2937-0560}
}
EUVIMED